IMP2/p62 induces genomic instability and an aggressive hepatocellular carcinoma phenotype
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Hepatocellular carcinoma (HCC) represents the third leading cause of cancer-related deaths and commonly develops in inflammatory environments. The IGF2 mRNA-binding protein IMP2-2/IGF2BP2-2/p62 was originally identified as an autoantigen in HCC. Aim of this study was to investigate a potential pathophysiological role of p62 in hepatocarcinogenesis. Human HCC tissue showed overexpression of IMP2, which strongly correlated with the fetal markers AFP and DLK1/Pref-1/FA-1 and was particularly elevated in tumors with stem-like features and hypervascularization. Molecular classification of IMP2-overexpressing tumors revealed an aggressive phenotype. Livers of mice overexpressing the IMP2 splice variant p62 highly expressed the stem cell marker DLK1 and secreted DLK1 into the blood. p62 was oncogenic: diethylnitrosamine (DEN)-treated p62 transgenic mice exhibited a higher tumor incidence and multiplicity than wild types. Tumors of transgenics showed a more aggressive and stem-like phenotype and displayed more oncogenic chromosomal aberrations determined with aCGH analysis. DEN-treated p62 transgenic mice exhibited distinct signs of inflammation, such as inflammatory cytokine expression and oxidative stress markers, that is, thiobarbituric acid-reactive substance (TBARS) levels. Reactive oxygen species (ROS) production was elevated in HepG2 cells, which either overexpressed p62 or were treated with DLK1. p62 induced this ROS production by a DLK1-dependent induction and activation of the small Rho-GTPase RAC1, activating NADPH oxidase and being overexpressed in human HCC. Our data indicate that p62/IMP2 promotes hepatocarcinogenesis by an amplification of inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Park, E. J., Lee, J. H., Yu, G.-Y., He, G., Ali, S. R., Holzer, R. G., Österreicher, C. H., Takahashi, H., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.052 · Cited by 1,764 · cited 2×
“5 or 5 weeks and were killed 48 h later.(19,39) For tumor induction, p62 transgenic mice and wt littermates were injected with 5 mg/kg BW at the age of 2 weeks.”
BackgroundMethodTranscriptome classification of HCC is related to gene alterations and to new therapeutic targets
Boyault, S., Rickman, D. S., de Reyniès, A., Balabaud, C., Rebouissou, S., Jeannot, E., Hérault, A., Saric, J., Belghiti, J., Franco, D., et al. (2007) · Hepatology · doi:10.1002/hep.21467 · Cited by 1,258
Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238 · cited 8×
“In order to connect IMP2,AFP, andDLK1 overexpression to already known molecular subsets of HCC,16 we performed hierarchical clustering of data set GSE14520 according to the marker genes identified by Hoshida et al.17 for three HCC Cell Death and Disease subtypes in mouse and by Chiang et al.18 for five HCC subtypes in…”
MethodInfluentialFocal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma
Chiang, D. Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., LeBlanc, A. C., Donovan, D. J., Thung, S. N., Solé, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0742 · Cited by 719
EpCAM and α-Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma
Yamashita, T., Forgues, M., Wang, W., Kim, J. W., Ye, Q., Jia, H., Budhu, A., Zanetti, K. A., Chen, Y., Qin, L.-X., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6013 · Cited by 717
Ahn, S., Jang, S. J., Shim, J. H., Kim, D., Hong, S., Sung, C. O., Baek, D., Haq, F., Ansari, A. A., Lee, S. Y., et al. (2014) · Hepatology · doi:10.1002/hep.27198 · Cited by 424
Oncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation
Ogrunc, M., Di Micco, R., Liontos, M., Bombardelli, L., Mione, M., Fumagalli, M., Gorgoulis, V. G., & d'Adda di Fagagna, F. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.16 · Cited by 328
Dai, N., Zhao, L., Wrighting, D., Krämer, D., Majithia, A., Wang, Y., Cracan, V., Borges-Rivera, D., Mootha, V. K., Nahrendorf, M., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.03.006 · Cited by 188
Overexpression of the IGF2-mRNA binding protein p62 in transgenic mice induces a steatotic phenotype
Tybl, E., Shi, F.-D., Kessler, S. M., Tierling, S., Walter, J., Bohle, R. M., Wieland, S., Zhang, J., Tan, E. M., & Kiemer, A. K. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.034 · Cited by 65 · cited 5×
“p62 transgenic mice expressing the transgene exclusively in the liver were established as previously described.(10) For the short-term experiment, p62 transgenic (p62 tg) mice and matched wt littermates were treated with 100 mg/kg body weight (BW) DEN i.”
BackgroundMethodInfluentialSelf-citationLiu, W., Li, Z., Xu, W., Wang, Q., & Yang, S. (2013) · Scandinavian Journal of Immunology · doi:10.1111/sji.12032 · Cited by 33
Cited by
Xu, X., Yu, Y., Zong, K., Lv, P., & Gu, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1470-y · Cited by 203
Dolton, G., Rius, C., Wall, A., Szomolay, B., Bianchi, V., Galloway, S. A. E., Hasan, M. S., Morin, T., Caillaud, M. E., Thomas, H. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.06.020 · Cited by 153
The Diverse Functions of IMP2/IGF2BP2 in Metabolism
Dai, N. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.05.007 · Cited by 114
Dai, N., Ji, F., Wright, J., Minichiello, L., Sadreyev, R., & Avruch, J. (2017) · eLife · doi:10.7554/elife.27155 · Cited by 103
“IMP2 is best considered a tumor promoter rather than an oncogene; although mice with transgenic overexpression of IMP2 in liver exhibit a higher tumor burden after diethylnitrosamine-induced hepatotoxicity (Kessler et al., 2015), IMP2 has not as yet been shown capable of initiating tumorigenesis.”
First Small-Molecule Inhibitors Targeting the RNA-Binding Protein IGF2BP2/IMP2 for Cancer Therapy
Dahlem, C., Abuhaliema, A., Kessler, S. M., Kröhler, T., Zoller, B. G. E., Chanda, S., Wu, Y., Both, S., Müller, F., Lepikhov, K., et al. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00833 · Cited by 70
Self-citationXing, M., Li, P., Wang, X., Li, J., Shi, J., Qin, J., Zhang, X., Ma, Y., Francia, G., & Zhang, J.-Y. (2019) · Cancers · doi:10.3390/cancers12010007 · Cited by 39
RHPN1-AS1 Drives the Progression of Hepatocellular Carcinoma via Regulating miR-596/IGF2BP2 Axis
Fen, H., Hongmin, Z., Wei, W., Chao, Y., Yang, Y., Bei, L., & Zhihua, S. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612825666191105104549 · Cited by 38
Czepukojc, B., Abuhaliema, A., Barghash, A., Tierling, S., Naß, N., Simon, Y., Körbel, C., Cadenas, C., van Hul, N., Sachinidis, A., et al. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00179 · Cited by 20
Self-citationMashayekhi, V., Schomisch, A., Rasheed, S., Aparicio-Puerta, E., Risch, T., Yildiz, D., Koch, M., Both, S., Ludwig, N., Legroux, T. M., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01701-y · Cited by 14
Self-citation
Metadata
- Authors
- Kessler, S. M., Laggai, S., Barghash, A., Schultheiss, C. S., Lederer, E., Artl, M., Helms, V, Haybaeck, J., & Kiemer, A. K.
- Venue
- Cell Death & Disease
- Published
- 2015-10-01
- Volume
- 6
- Issue
- 10
- Pages
- e1894-e1894
- ISSN
- 2041-4889 (ISSN-L)
- OpenAlex
- W2210774936
- Cited by
- 92
- References
- 10
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.